Complete Freund's Adjuvant, 4 mg/mL
Please register to view price.
Please inquire for bulk pricing.
Complete Freund's Adjuvant (CFA or FCA) is 4 mg/ml M. Tuberculosis (non-viable) in mineral oil.
Overview
Complete Freund’s Aduvant (CFA or FCA) is widely used in immunological research for the
preparation of antigen-adjuvant emulsions in laboratory animal studies. CFA contains cell wall
components of heat killed Mycobacterium tuberculosis and is often used for the initial injection
that stimulates an enhanced immune response.
Data/Specifications
Format: Tan liquid with particles.
Composition: 4 mg/mL M. Tuberculosis H37 RA (non-viable) in mineral oil.
Application: For in-vivo/in-vitro studies. Typically used for the boost of an immune response.
Storage: Keep tightly closed. Store at 2-8 °C. Do not freeze.
Literature/Support
Complete Freund's Adjuvant Insert (PDF)
References/Citations:
Casanova-Vallve, N., Constantin-Teodosiu, D., Filer, A., Hardy, R. S., Greenhaff, P. L., & Chapman, V. (2020). Skeletal muscle dysregulation in rheumatoid arthritis: Metabolic and molecular markers in a rodent model and patients. PloS one, 15(7), e0235702.
Alvarez, P., Augustín, J. J., Tamayo, E., Iglesias, M., Acinas, O., Mendiguren, M. A., ... & Merino, R. (2020). Therapeutic effects of anti-Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor treatment in psoriasis and arthritis. Arthritis & Rheumatology.
Poolman, T. M., Gibbs, J., Walker, A. L., Dickson, S., Farrell, L., Hensman, J., ... & Rattray, M. (2019). Rheumatoid arthritis reprograms circadian output pathways. Arthritis Research & Therapy, 21(1), 47.
Chuang, H. C., Chen, Y. M., Chen, M. H., Hung, W. T., Yang, H. Y., Tseng, Y. H., & Tan, T. H. (2019). AhR–ROR-γt complex is a therapeutic target for MAP4K3/GLKhighIL-17A high subpopulation of systemic lupus erythematosus. The FASEB Journal, 33(10), 11469-11480.
Mariola Kurowska-Stolarska, Stefano Alivernini, Emma Garcia Melchor, et. al. MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Communications (2017) 8, Article number 15877
Chris AH Hansel, Lindsay M MacLellan, Rachek S Oldham, et. al. The atypical chemokine receptor ACKR2 suppresses Th17 responses to protein autoantigens. Immunology and Cell Biology (2014), 1-10
Campo GM, Avenoso A, D'Ascola A, Nastasi G, et.al. Combined Treatment With Hyaluronan Inhibitor Pep-1 and a Selective Adenosine A2 Receptor Agonist Reduces Inflammation in Experimental Arthritis. Innate Immun. 2013;19(5):462-478
Eveline Trachsel, Frank Bootz, Michela Silacci, et. al. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Research & Therapy (2007), 9:R9